147283-71-4

Upstream product

• 100-39-0 benzyl bromide 
• 147269-68-9 3-<<(benzyloxy)carbonyl>amino>-5-iodopyrid-2-one 
• 7440-66-6 zinc 
• 147269-67-8 3-(benzyloxycarbonylamino)pyrid-2-one 
• 33630-99-8 3-amino-2-pyridone 
• 6332-56-5 3-nitropyridone 

Downstream Products

• 147283-72-5 (5-Benzyl-3-benzyloxycarbonylamino-2-oxo-2H-pyridin-1-yl)-acetic acid ethyl ester 
• 184710-75-6 2-(3-benzyloxycarbonylamino-5-benzyl-2-oxo-1,2-dihydro-1-pyridyl)acetic acid 
• 147313-63-1 2-(3-Amino-5-benzyl-2-oxo-2H-pyridin-1-yl)-N-(3,3,3-trifluoro-1-isopropyl-2-oxo-propyl)-acetamide 
• 147268-12-0 N-{5-Benzyl-2-oxo-1-[(3,3,3-trifluoro-1-isopropyl-2-oxo-propylcarbamoyl)-methyl]-1,2-dihydro-pyridin-3-yl}-oxalamic acid methyl ester 
• 147283-69-0 {5-Benzyl-2-oxo-1-[(3,3,3-trifluoro-2-hydroxy-1-isopropyl-propylcarbamoyl)-methyl]-1,2-dihydro-pyridin-3-yl}-carbamic acid benzyl ester 
• 147267-87-6 2-(5-Benzyl-3-benzyloxycarbonylamino-2-oxo-1,2-dihydro-1-pyridyl)-N-(3,3,3-trifluoro-1-isopropyl-2-oxopropyl)acetamide 

Relevant academic research and scientific papers

Non-peptidic inhibitors of human leukocyte elastase. 1. The design and synthesis of pyridone-containing inhibitors

Human leukocyte elastase (HLE) is a serine protease produced by neutrophils that has been implicated in diseases such as amphysema and cystic fibrosis. An HLE inhibitor may have therapeutic value in these diseases. An active site model of HLE bound to a t

HETEROCYCLIC AMIDE COMPOUNDS AND PHARMACEUTICAL USE OF THE SAME

Heterocyclic amide compounds of the formula (I) STR1 wherein each symbol is as defined in the specification, pharmacologically acceptable salts thereof, pharmaceutical compositions thereof and pharmaceutical use thereof. The heterocyclic amide compounds and pharmacologically acceptable salts thereof of the present invention have superior inhibitory activity against chymase groups in mammals inclusive of human, and can be administered orally or parenterally. Therefore, they are useful as chymase inhibitors and can be effective for the prophylaxis and treatment of various diseases caused by chymase, such as those caused by angiotensin II.